Autolus Therapeutics plc
AUTL
$1.75
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 185.17% | -14.16% | 496.00% | 82.71% | 40.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 185.17% | -14.16% | 496.00% | 82.71% | 40.22% |
| Cost of Revenue | 39.58% | 1.37% | -4.59% | 115.62% | 42.32% |
| Gross Profit | -28.67% | -2.31% | 9.37% | -118.45% | -42.48% |
| SG&A Expenses | 73.77% | 90.03% | 100.12% | 137.59% | 106.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.33% | 45.87% | 41.58% | 64.34% | 43.51% |
| Operating Income | -39.83% | -49.39% | -37.18% | -63.58% | -43.69% |
| Income Before Tax | 4.41% | -5.92% | -5.15% | -94.89% | -65.14% |
| Income Tax Expenses | 205,400.00% | 29,023.08% | 8,136.84% | -99.79% | -100.01% |
| Earnings from Continuing Operations | 2.65% | -7.62% | -5.89% | -70.85% | -50.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.65% | -7.62% | -5.89% | -70.85% | -50.88% |
| EBIT | -39.83% | -49.39% | -37.18% | -63.58% | -43.69% |
| EBITDA | -40.33% | -50.25% | -37.94% | -65.95% | -45.96% |
| EPS Basic | 26.41% | 25.80% | 27.50% | -20.01% | 4.03% |
| Normalized Basic EPS | 27.61% | 27.05% | 26.74% | -51.80% | -8.46% |
| EPS Diluted | 26.41% | 25.80% | 27.50% | -20.01% | 4.03% |
| Normalized Diluted EPS | 27.61% | 27.05% | 26.74% | -51.80% | -8.46% |
| Average Basic Shares Outstanding | 27.30% | 43.05% | 46.67% | 47.70% | 53.22% |
| Average Diluted Shares Outstanding | 27.30% | 43.05% | 46.67% | 47.70% | 53.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |